{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:40:10Z","timestamp":1779241210167,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University Hospital of Zurich, Switzerland"},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real-world data on anatomically localized psoriasis and its response to systemic therapy across different age-groups and sexes is limited. This study aimed to evaluate the severity and distribution of psoriasis over time in female and male patients receiving systemic therapies, categorized by age within the Swiss psoriasis registry (SDNTT). Patient-data was obtained over 11\u00a0years through the SDNTT. The localized Psoriasis Area and Severity Index (locPASI) of the head, trunk, upper and lower extremities was analyzed over two years following the start of systemic non-\/biologic treatment. A total of 316 female and 517 male patients were analyzed. Male patients had a higher baseline locPASI for legs, trunk and arms (p\u2009&lt;\u20090.001), but not for the head (p\u2009=\u20090.961). The locPASI for the head in younger female patients (18\u201340\u00a0years) had a higher score than those aged 55\u2009+\u2009(p\u2009=\u20090.022) and after two years, middle aged (41\u201354) showed a lower score compared to younger patients (p\u2009=\u20090.045). Younger male patients revealed a lower score after two years of therapy in the leg- and arm-area compared to older (p\u2009=\u20090.018 and p\u2009=\u20090.048, respectively). Female patients on non-biologics had a fast initial response, converging with male patients\u2019 scores over 24\u00a0months. Over 75% locPASI reduction was observed for female head-area (81.4%), male trunk (82.7%) and legs (76.1%). Absolute locPASI\u2009\u2264\u20092 was achieved 3\u20136\u00a0months for all locations with interleukin (IL)-17, IL-12\/23 and IL-23-inhibitors, except for the legs of male patients on anti-IL-17 and female patients on anti-IL-12\/23 and -IL-23. After two years, male patients did not achieve a locPASI\u2009\u2264\u20092 for any biologic-treatment in the legs, nor for the arms on anti-TNF-\u03b1. Significant disparities in localized PASI were observed between female and male patients. The age, sex and severity of distinct localizations should be considered to optimize treatment goals.<\/jats:p>","DOI":"10.1007\/s00403-024-03375-5","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T12:02:21Z","timestamp":1727784141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psoriasis localization patterns in the Swiss Psoriasis Registry (SDNTT) over 11\u00a0years: an analysis by sex and age"],"prefix":"10.1007","volume":"316","author":[{"given":"Ion","family":"Birkenmaier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara Valeska","family":"Maul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iker","family":"Oyanguren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Sorbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schlapbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Heidemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Yawalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christian","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Micheroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Mainetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cozzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"K\u00fcndig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell P.","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"3375_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. The Lancet 397:1301\u20131315","journal-title":"The Lancet"},{"key":"3375_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Team I.a.M.o.P.a.A.C.I.p (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133:377\u2013385","journal-title":"J Invest Dermatol"},{"key":"3375_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2018.80718","volume":"56","author":"K Dopytalska","year":"2018","unstructured":"Dopytalska K, Sobolewski P, B\u0142aszczak A, Szyma\u0144ska E, Walecka I (2018) Psoriasis in special localizations. Reumatologia 56:392\u2013398","journal-title":"Reumatologia"},{"key":"3375_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/24755303231160683","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A et al (2023) Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities. J Psoriasis Psoriatic Arthr. https:\/\/doi.org\/10.1177\/24755303231160683","journal-title":"J Psoriasis Psoriatic Arthr"},{"key":"3375_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40257-017-0274-0","volume":"18","author":"D Hagg","year":"2017","unstructured":"Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M (2017) Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol 18:583\u2013590","journal-title":"Am J Clin Dermatol"},{"key":"3375_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/bjd.20387","volume":"185","author":"JT Maul","year":"2021","unstructured":"Maul JT et al (2021) Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol 185:1160\u20131168","journal-title":"Br J Dermatol"},{"key":"3375_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jdv.15324","volume":"33","author":"JT Maul","year":"2019","unstructured":"Maul JT et al (2019) Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol 33:700\u2013708","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3375_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1468-3083.2011.04026.x","volume":"26","author":"D White","year":"2012","unstructured":"White D, O\u2019Shea SJ, Rogers S (2012) Do men have more severe psoriasis than women? J Eur Acad Dermatol Venereol 26:126\u2013127","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3375_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/ced.14218","volume":"45","author":"M Napolitano","year":"2020","unstructured":"Napolitano M et al (2020) Sex- and gender-associated clinical and psychosocial characteristics of patients with psoriasis. Clin Exp Dermatol 45:705\u2013711","journal-title":"Clin Exp Dermatol"},{"key":"3375_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/571912","volume":"2013","author":"R Ceovic","year":"2013","unstructured":"Ceovic R et al (2013) Psoriasis: female skin changes in various hormonal stages throughout life\u2014puberty, pregnancy, and menopause. Biomed Res Int 2013:571912","journal-title":"Biomed Res Int"},{"key":"3375_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1684\/ejd.2019.3605","volume":"29","author":"JP Allam","year":"2019","unstructured":"Allam JP et al (2019) Low serum testosterone levels in male psoriasis patients correlate with disease severity. Eur J Dermatol 29:375\u2013382","journal-title":"Eur J Dermatol"},{"key":"3375_CR12","first-page":"257","volume":"61","author":"CM Mowad","year":"1998","unstructured":"Mowad CM et al (1998) Hormonal influences on women with psoriasis. Cutis 61:257\u2013260","journal-title":"Cutis"},{"key":"3375_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s40257-018-0388-z","volume":"19","author":"S Singh","year":"2018","unstructured":"Singh S et al (2018) Effect of age of onset of psoriasis on clinical outcomes with systemic treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Am J Clin Dermatol 19:879\u2013886","journal-title":"Am J Clin Dermatol"},{"key":"3375_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000010","volume":"8","author":"C Guillet","year":"2022","unstructured":"Guillet C, Seeli C, Nina M, Maul LV, Maul JT (2022) The impact of gender and sex in psoriasis: what to be aware of when treating women with psoriasis. Int J Womens Dermatol 8:e010","journal-title":"Int J Womens Dermatol"},{"key":"3375_CR15","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","volume":"22","author":"E Camela","year":"2022","unstructured":"Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M (2022) New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther 22:1431\u20131433","journal-title":"Expert Opin Biol Ther"},{"key":"3375_CR16","unstructured":"ClinicalTrials.gov Identifier: NCT01706692; Swiss Dermatology Network of Targeted Therapies (SDNTT); 2012. (Bethesda (MD): National Library of Medicine (US). 2000; https:\/\/clinicaltrials.gov\/study\/NCT01706692 - Last Access: January 2024)"},{"key":"3375_CR17","unstructured":"SDNTT (Swiss Dermatology Network for Targeted Therapies) - https:\/\/www.sdntt.ch\/de\/. (Last access: Sept. 2022)"},{"key":"3375_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/jdv.19730","volume":"38","author":"F Verardi","year":"2023","unstructured":"Verardi F et al (2023) Sex differences in adverse events from systemic treatments for psoriasis: a decade of insights from the Swiss Psoriasis Registry (SDNTT). J Eur Acad Dermatol Venereol 38:719\u2013731","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3375_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1159\/000455042","volume":"232","author":"P Jungo","year":"2016","unstructured":"Jungo P et al (2016) Superiority in quality of life improvement of biologics over conventional systemic drugs in a swiss real-life psoriasis registry. Dermatology 232:655\u2013663","journal-title":"Dermatology"},{"key":"3375_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1159\/000452740","volume":"232","author":"JT Maul","year":"2016","unstructured":"Maul JT et al (2016) Efficacy and survival of systemic psoriasis treatments: an analysis of the Swiss Registry SDNTT. Dermatology 232:640\u2013647","journal-title":"Dermatology"},{"key":"3375_CR21","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/jdv.15983","volume":"33","author":"S Cazzaniga","year":"2019","unstructured":"Cazzaniga S et al (2019) Linkage between patients\u2019 characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. J Eur Acad Dermatol Venereol 33:2313\u20132318","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3375_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00403-019-01945-6","volume":"311","author":"M Drach","year":"2019","unstructured":"Drach M et al (2019) Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Arch Dermatol Res 311:753\u2013760","journal-title":"Arch Dermatol Res"},{"key":"3375_CR23","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2340\/00015555-3221","volume":"99","author":"F Anzengruber","year":"2019","unstructured":"Anzengruber F et al (2019) Smoking does not alter the therapy response to systemic anti-psoriatic therapies: a two-country, multi-centre, prospective. Non-interventional Study Acta Derm Venereol 99:871\u2013877","journal-title":"Non-interventional Study Acta Derm Venereol"},{"issue":"2","key":"3375_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/24755303231217492","volume":"9","author":"ML Nielsen","year":"2023","unstructured":"Nielsen ML et al (2023) Predicting psoriatic arthritis in psoriasis patients \u2013 a Swiss Registry Study. J Psoriasis Psoriatic Arthr 9(2):41\u201350","journal-title":"J Psoriasis Psoriatic Arthr"},{"key":"3375_CR25","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/jdv.15983","volume":"33","author":"S Cazzaniga","year":"2019","unstructured":"Cazzaniga S et al (2019) Linkage between patients\u2019 characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. J Eur Acad Dermatol Venereol 33:2313\u20132318","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3375_CR26","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A et al (2020) EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 34:2461\u20132498","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3375_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A et al (2021) EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 35:281\u2013317","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3375_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U (1978) Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica 157:238\u2013244","journal-title":"Dermatologica"},{"key":"3375_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","volume":"141","author":"DM Ashcroft","year":"1999","unstructured":"Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141:185\u2013191","journal-title":"Br J Dermatol"},{"key":"3375_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1214\/aoms\/1177730491","volume":"18","author":"HB Mann","year":"1947","unstructured":"Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Annals Mathe Statist 18:50\u201360","journal-title":"Annals Mathe Statist"},{"key":"3375_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2307\/3001968","volume":"1","author":"F Wilcoxon","year":"1945","unstructured":"Wilcoxon F (1945) Individual comparisons by ranking methods. Biometrics Bulletin 1:80\u201383","journal-title":"Biometrics Bulletin"},{"key":"3375_CR32","unstructured":"Fisher RA (1934) Statistical methods for research workers, 5th ed, (Edinburgh, Oliver and Boyd, 1934)"},{"key":"3375_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","volume":"52","author":"SS Shapiro","year":"1965","unstructured":"Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples)\u2020. Biometrika 52:591\u2013611","journal-title":"Biometrika"},{"key":"3375_CR34","doi-asserted-by":"crossref","unstructured":"Student (1908) The Probable Error of a Mean. Biometrika 6:1\u201325","DOI":"10.1093\/biomet\/6.1.1"},{"key":"3375_CR35","unstructured":"Team RC (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/."},{"key":"3375_CR36","unstructured":"World Medical Association (WMA) (2022) Decleration of Helsinki (Update 6th September 2022). Link: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/ (Last access: 20. December 2022)"},{"key":"3375_CR37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000512930","volume":"237","author":"JT Maul","year":"2021","unstructured":"Maul JT et al (2021) Topical treatment of psoriasis vulgaris: The Swiss treatment pathway. Dermatology 237:166\u2013178","journal-title":"Dermatology"},{"key":"3375_CR38","first-page":"215","volume":"25","author":"Z Sojevi\u0107 Timotijevi\u0107","year":"2017","unstructured":"Sojevi\u0107 Timotijevi\u0107 Z et al (2017) The impact of changes in psoriasis area and severity index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat 25:215\u2013222","journal-title":"Acta Dermatovenerol Croat"},{"key":"3375_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/09546634.2017.1365114","volume":"29","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A et al (2018) Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatol Treat 29:220\u2013229","journal-title":"J Dermatol Treat"},{"key":"3375_CR40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1067\/mjd.2000.101596","volume":"42","author":"RS Hotard","year":"2000","unstructured":"Hotard RS, Feldman SR, Fleischer AB Jr (2000) Sex-specific differences in the treatment of severe psoriasis. J Am Acad Dermatol 42:620\u2013623","journal-title":"J Am Acad Dermatol"},{"key":"3375_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063619","volume":"8","author":"D H\u00e4gg","year":"2013","unstructured":"H\u00e4gg D, Eriksson M, Sundstr\u00f6m A, Schmitt-Egenolf M (2013) The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One 8:e63619","journal-title":"PLoS One"},{"key":"3375_CR42","first-page":"450","volume":"3","author":"D Colombo","year":"2022","unstructured":"Colombo D et al (2022) The CANOVA Study Real-World Evidence of biologic treatments in moderate-severe psoriasis in Italy: a gender perspective. Womens Health Rep (New Rochelle) 3:450\u2013457","journal-title":"Womens Health Rep (New Rochelle)"},{"key":"3375_CR43","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Fern\u00e1ndez CP et al (2021) Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM Prospective Cohort. Acta Derm Venereol 101, adv00354","DOI":"10.2340\/00015555-3711"},{"key":"3375_CR44","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jdv.16073","volume":"34","author":"ND Loft","year":"2020","unstructured":"Loft ND, Vaengebjerg S, Halling A-S, Skov L, Egeberg A (2020) Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol 34:1151\u20131160","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3375_CR45","first-page":"1","volume":"157","author":"P Gisondi","year":"2022","unstructured":"Gisondi P et al (2022) Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol 157:1\u201378","journal-title":"Ital J Dermatol Venerol"},{"key":"3375_CR46","first-page":"934","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A et al (2021) German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges 19:934\u2013150","journal-title":"J Dtsch Dermatol Ges"},{"key":"3375_CR47","first-page":"1092","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A et al (2021) German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges 19:1092\u20131115","journal-title":"J Dtsch Dermatol Ges"},{"issue":"Suppl 4","key":"3375_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-0625.2004.00255.x","volume":"13","author":"CC Zouboulis","year":"2004","unstructured":"Zouboulis CC, Degitz K (2004) Androgen action on human skin \u2013 from basic research to clinical significance. Exp Dermatol 13(Suppl 4):5\u201310","journal-title":"Exp Dermatol"},{"key":"3375_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.0022-202X.2004.12645.x","volume":"123","author":"N Kanda","year":"2004","unstructured":"Kanda N, Watanabe S (2004) 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol 123:319\u2013328","journal-title":"J Invest Dermatol"},{"key":"3375_CR50","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jid.2017.11.015","volume":"138","author":"JT Rachael","year":"2018","unstructured":"Rachael JT et al (2018) Intentional and unintentional medication non-adherence in psoriasis: the role of patients\u2019 medication beliefs and habit strength. J Investig Dermatol 138:785\u2013794","journal-title":"J Investig Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03375-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T18:02:52Z","timestamp":1729879372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03375-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3375"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03375-5","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IB: is an employee of the University Hospital of Z\u00fcrich and PhD candidate at the University of Z\u00fcrich and has declared no conflict of interest.  LVM: Outside of the submitted work, LVM has served as advisor and\/or received speaking fees and\/or grants and\/or participated in clinical trials sponsored by Almirall, Amgen, BMS, Canfield, Eli Lilly, Incyte, MSD, Novartis, Pierre Fabre, Roche, and Sanofi.  CSor: has declared no conflict of interest.  IO: has declared no conflict of interest.  FF: Unrelated to this project FF has received speaking fees from Eli Lilly.   CSchla: With no relation to the present manuscript, Prof. Schlapbach has received honoraria as adviser or speaker for Abbvie, Almirall, BMS, Incyte, LEO Pharma, Lilly, Kiowa Kirin, Novartis, Pfizer and Sanofi and has received research funding from PPM Services.  KH: With no relation to the present manuscript, KH has been an advisor for and\/or has received research support from Abbvie, Almirall, Galderma, Sanofi, UCB.  NY: Outside of the submitted work, NY has served as advisor and\/or received speaking fees and\/or grants and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim,  Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi-Genzyme, UCB.  WHB: has received honoraria as a speaker and\/or consultant from Abbvie, Almirall, Amgen, BMS, Janssen, Leo, Lilly, Novartis and UCB.  HCR: Dr. Ring has received support for attending meeting from Pfizer Inc.  JPT: Outside of the submitted work Prof. Thyssen has been an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme. Prof. Thyssen is currently employed by LEO Pharma.  AE: Outside of the submitted work, Prof. Egeberg has received research funding from Almirall, Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, Boehringer Ingelheim, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and\/or speaker from Amgen, AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Gal\u00e1pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen Pharmaceuticals, and is currently employed by LEO Pharma.  RM: has declared no conflict of interest.  SFT: has been a speaker and\/or advisor for and\/or has received research support from Abbvie, Almirall, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi, Symphogen, UCB, and Union therapeutics.  CM: Advisory activities outside of the submitted work for AbbVie, Celgene, Eli-Lilly, Galderma, Sanofi and Novartis.  AC: Advisory activities outside of the submitted work for AbbVie, Almirall, Amgen, Galderma, Leo Pharma, Janssen-Cilag, Novartis and UCB.  TK: has intermittent, project focused consulting and\/or advisory relationships with Leo Pharma, Janssen-Cilag, Eli Lilly, Pierre Fabre, Sanofi-Genzyme, Abbvie, Biomed AG, Novartis, Almirall, Bristol-Myers Squibb, Galderma, L\u2019Or\u00e9al\/LaRoche-Posay, Merck-Sharp & Dohme, Zur Rose AG, Allergy Therapeutics AG, Derma2go AG, Oncobit AG, EVAX AG, Saiba Biotechnology AG, Saiba Animal Health AG, AltiBio Corp, Encoded Corp, Mabylon AG, MannKind Corp and XBiotech Corp.  MPL: has declared no conflict of interest.  AAN: declares being a consultant and advisor and\/or receiving speaking fees and\/or grants and\/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, Biomed, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Louis-Widmer AG, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre Pharma, Regeneron, Sandoz, Sanofi and UCB.  JTM: has served as advisor and\/or received speaking fees and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, Incyte, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This research was approved by the University Hospital of Z\u00fcrich review board. The SDNTT registry is approved by the Ethics Committee Northwest and Central Switzerland (EKNZ 62\/11) and conducted in accordance with the declaration of Helsinki. The registry is registered with the ClinicalTrials.gov ID NCT01706692.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Basic tools were used to improve vocabulary and grammar. No AI, language model, machine\u00a0learning, or similar\u00a0technologies were used in the creation or editing of any of the content in this submission. All content is unique and original.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI or language model (LLM)"}},{"value":"All patients recruited into the SDNTT registry gave their informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"654"}}